A. Cakana

发表

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Bin Jiang, Ofer Shpilberg, D. Esseltine, 2008, The New England journal of medicine.

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.

D. Esseltine, M. Dimopoulos, J. Miguel, 2010, Blood.

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

H. van de Velde, A. Cakana, M. Bayssas, 2007, Haematologica.

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

M. Dimopoulos, P. Richardson, H. van de Velde, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

F. Cavalli, H. van de Velde, J. Drach, 2017, Haematologica.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia

B. Pégourié, S. Iacobelli, G. Gahrton, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.

H. van de Velde, D. Reece, Y. Elsayed, 2011, QJM : monthly journal of the Association of Physicians.

D. Esseltine, P. Richardson, J. S. San Miguel, 2012, European journal of haematology.

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma

K. O'Byrne, D. Fennell, P. Baas, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

H. van de Velde, P. Moreau, X. Leleu, 2012, Haematologica.

patients with relapsed systemic AL amyloidosis : results of a phase 1 / 2 Efficacy and safety of once-weekly and twice-weekly bortezomib

D. Esseltine, D. Reece, G. Merlini, 2011 .

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

D. Esseltine, H. van de Velde, D. Reece, 2011, Blood.

Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial

D. Esseltine, M. Dimopoulos, P. Richardson, 2011, British journal of haematology.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

D. Reece, Y. Elsayed, G. Merlini, 2009, Blood.

Proteasome Inhibition and Hematopoietic Stem Cell Transplantation in Multiple Myeloma

A. Cakana, H. Velde, 2013 .

Excessive neutrophil recruitment promotes typical T-helper 17 responses in Coronavirus disease 2019 patients

T. Mduluza, A. Cakana, E. Sibanda, 2022, PloS one.

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

L. Garrison, H. van de Velde, M. Duh, 2013, The oncologist.

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sepsis in cancer patients residing in Zimbabwe: spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns

Prichard T Mapondera, A. Cakana, T. Nyazika, 2019, BMC Infectious Diseases.

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

J. Moreaux, D. Hose, C. Heirman, 2018, Cancer research.

study patients with relapsed systemic AL amyloidosis: results of a phase 1/2 Efficacy and safety of once-weekly and twice-weekly bortezomib in

D. Esseltine, D. Reece, G. Merlini, 2011 .

amyloidosis: results of a phase 1 dose-escalation study Weekly and twice-weekly bortezomib in patients with systemic AL

Y. Elsayed, G. Merlini, U. Hegenbart, 2009 .

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2012, Clinical Pharmacokinetics.

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

D. Esseltine, H. Goldschmidt, P. Sonneveld, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

D. Esseltine, M. Duh, A. Cakana, 2010 .

The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

D. Esseltine, L. Garrison, M. Duh, 2009 .

Use of packed red cells in a major hospital in Harare, Zimbabwe.

A. Cakana, J. Adewuyi, A. Mandisodza, 1999, The Central African journal of medicine.

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

D. Esseltine, J. Miguel, A. Oriol, 2016, Annals of Hematology.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

D. Esseltine, D. Reece, V. Kukreti, 2014, Blood.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

R. Greil, R. Hájek, B. Paiva, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma.

M. Dimopoulos, A. Palumbo, P. Richardson, 2007 .

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

M. Dimopoulos, J. Miguel, P. Richardson, 2008 .

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma

D. Esseltine, H. Goldschmidt, M. Dimopoulos, 2011, European journal of haematology.

melphalan-prednisone versus melphalan-prednisone analysis of the phase 3 VISTA study of bortezomib plus therapy: diagnosed multiple myeloma patients treated with nonintensive Superior outcomes associated with complete response in newly

D. Esseltine, A. Palumbo, J. Miguel, 2012 .

A217 Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

M. Dimopoulos, K. Anderson, P. Richardson, 2009 .

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

D. Esseltine, M. Dimopoulos, A. Palumbo, 2011, European journal of haematology.

Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.

R. Greil, R. Hájek, H. Ludwig, 2009 .

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

P. Sonneveld, A. Nagler, R. Hájek, 2016, Cancer.

Spontaneous chronic subdural hematomas in human immunodeficiency virus-infected patients with normal platelet count and no appreciable brain atrophy: Two case reports and review of literature

A. Cakana, K. Kalangu, Luxwell Jokonya, 2016, Surgical neurology international.

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

D. Esseltine, M. Dimopoulos, A. Palumbo, 2008 .

Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

J. Miguel, P. Richardson, A. Regnault, 2009 .

A352 Impact of Complete Response on Quality of Life in Newly Diagnosed Multiple Myeloma Patients

J. Miguel, P. Richardson, A. Regnault, 2009 .

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

M. Dimopoulos, J. Miguel, P. Richardson, 2008 .

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

M. Dimopoulos, A. Palumbo, J. Miguel, 2008 .

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

D. Esseltine, M. Dimopoulos, A. Palumbo, 2011 .

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2011 .

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2009 .

Is antenatal antibody screening worthwhile in the Zimbabwean population?

A. Cakana, L. Ngwenya, 2000, Central African Journal of Medicine.

A172 Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

M. Dimopoulos, A. Palumbo, J. Miguel, 2009 .

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

A. Palumbo, P. Richardson, N. Brun, 2013 .

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

J. Moreaux, D. Hose, C. Heirman, 2018, Cancer research.

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy : analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

D. Esseltine, M. Dimopoulos, A. Palumbo, 2010 .